MYC and Burkitt lymphoma: Further evidence for a role of the BCR/PI3K/AKT pathway in BL pathogenesis was provided by Varano and colleagues, who demonstrated in a MYC transgenic mouse model of BL that BCR-negative lymphoma cells can proliferate and survive in vitro but exhibit a competitive growth disadvantage compared to their BCR-positive counterparts [109].